VGF and early-onset autosomal dominant Alzheimer disease: Recent studies conducted by the NIH Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD) consortium have further identified reduced VGF levels in the brains of AD subjects that correlate with mean amyloid plaque density, Clinical Dementia Rating (CDR) and Braak scores, with multi-omic network analysis further indicating that VGF is a key driver of AD pathogenesis and progression [15, 16].